Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a single institution phase II study of a reduced intensity conditioning (RIC)
followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with
diagnosis of hematologic malignancy. Conditioning will consists of fludarabine,
cyclophosphamide, melphalan and total body irradiation (TBI) preparative regimen with a
melphalan dose reduction for patients ≥55 years old and those with HCT Comorbidity Index (CI)
>3. This study uses a two-stage phase II design with accrual goal of 84 patients, using 28
patients separately for arms A, C and D